Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Natural Resource Stocks -- Ignore unavailable to you. Want to Upgrade?

To: isopatch who wrote (7227)	2/4/2004 12:52:26 PM
From: Christopher Loe	Respond to of 108747

Entries at 2.81, 2.86 & today I paid up at 3.21. I'm not finished yet, but would like to buy a little cheaper. From my research, a target of $10, not my target, someone else's that is close to the company. He travels to China once a month to check on their progress. SARS vaccine is now in trial stage & has been given to 20 people. They are the only company to be approved for clinical trials. Also, in the trial stage of a combination Hepatitis A & B which only Glaxo has, but can be given to infants on up, where Glaxo's vaccine starts at the age of 16. Hepatitis is prevalent in China. Worth the risk in MVHO. Chris